Cassady E. Rupert

Cassady E. Rupert

Auto-generated profile, based on publicly available information

Cassady E. Rupert

Propria LLC, Branford, Connecticut, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Biomarker Insights
Verified
Journal Article
Open access
CRCassady E. Rupert
Cassady E. Rupert
KCKareen L. K. Coulombe
Kareen L. K. Coulombe
Neuregulin-1 (NRG-1) and its signaling receptors, erythroblastic leukemia viral oncogene homologs (ErbB) 2, 3, and 4, have been implicated in both cardiomyocyte development and disease, as well as in homeostatic cardiac function. NRG-1/ErbB signaling is involved in a multitude of cardiac processes ranging from myocardial and cardiac conduction system development to angiogenic support of cardiomyocytes, to cardioprotective effects upon injury. Numerous studies of NRG-1 employ a variety of platforms, including in vitro assays, animal models, and human clinical trials, with equally varying and, sometimes, contradictory outcomes. NRG-1 has the potential to be used as a therapeutic tool in stem cell therapies, tissue engineering applications, and clinical diagnostics and treatment. This review presents a concise summary of the growing body of literature to highlight the temporally persistent significance of NRG-1/ErbB signaling throughout development, homeostasis, and disease in the heart, specifically in cardiomyocytes.

1 January 2017 in Stem Cells International
Verified
Journal Article
Open access
PDF file
CRCassady E. Rupert
Cassady E. Rupert
KCKareen L. K. Coulombe
Kareen L. K. Coulombe
Insulin-like growth factor 1 (IGF1) and neuregulin-1β (NRG1) play important roles during cardiac development both individually and synergistically. In this study, we analyze how 3D cardiac tissue engineered from human embryonic stem cell- (hESC-) derived cardiomyocytes and 2D-plated hESC-cardiomyocytes respond to developmentally relevant growth factors both to stimulate maturity and to characterize the therapeutic potential of IGF1 and NRG1. When administered to engineered cardiac tissues, a significant decrease in active force production of ~65% was measured in all treatment groups, likely due to changes in cellular physiology. Developmentally related processes were identified in engineered tissues as IGF1 increased hESC-cardiomyocyte proliferation 3-fold over untreated controls and NRG1 stimulated oxidative phosphorylation and promoted a positive force-frequency relationship in tissues up to 3 Hz. hESC-cardiomyocyte area increased significantly with NRG1 and IGF1 + NRG1 treatment in 2D culture and gene expression data suggested increased cardiac contractile components in engineered tissues, indicating the need for functional analysis in a 3D platform to accurately characterize engineered cardiac tissue response to biochemical stimulation. This study demonstrates the therapeutic potential of IGF1 for boosting proliferation and NRG1 for promoting metabolic and contractile maturation in engineered human cardiac tissue.

1 April 2018 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
MLMan Liu
Man Liu
GSGuangbin Shi
Guangbin Shi
AZAnyu Zhou
Anyu Zhou
CRCassady E. Rupert
Cassady E. Rupert
KCKareen L.K. Coulombe
Kareen L.K. Coulombe
Samuel C. DudleySamuel C. Dudley
Samuel C. Dudley

3 August 2016 in Cellular and Molecular Bioengineering
Verified
Journal Article
Closed access
PDF file
CRCassady E. Rupert
Cassady E. Rupert
HCHeidi H. Chang
Heidi H. Chang
KCKareen L. K. Coulombe
Kareen L. K. Coulombe

1 March 2023 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
CRC. Rupert
C. Rupert
JLJ. E. López
J. E. López
ECE. Cortez-Toledo
E. Cortez-Toledo
OCO. De la Cruz Cabrera
O. De la Cruz Cabrera
NCN. C. Chesler
N. C. Chesler
ABAnthony Baker
Anthony Baker
Chronic stimulation of α1A-adrenergic receptors (α1A-ARs) is known to mediate therapeutic effects in animal heart failure models. To investigate the effects of chronic α1A-AR stimulation in human cardiomyocytes, we tested engineered heart tissue (EHT) created with iPSC-derived cardiomyocytes. RNA-seq analysis confirmed human EHT expressed α1A-ARs. Chronic (2 wk) α1A-AR stimulation with A61603 (10 nM) increased length-dependent activation (LDA) of contraction. Chronic α1A-AR stimulation might be beneficial for treating human heart failure by restoring LDA.